EuroNanoMed has recently applied for an extension of its activities in Europe and beyond. The ENM III application has been positively evaluated and is currently undergoing the Grant Agreement Preparation phase with the Commission.
The ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to foster the competiveness of European nanomedicine actors, taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the Nanomedicine Strategic Research and Innovation Agenda.
ENM III is expected to start and launch the first joint call in autumn 2016, whichwill be co-funded by ENM III partners and the EC.
Following the co-funded call, three additional joint transnational calls will be organized and strategic activities will be conducted in collaboration with key initiatives in the field.
ENM III actions will strength their focus on translation of project results to clinical applications and industry needs.
EuroNanoMed III is funded under the ERA-NET Cofund scheme of the Horizon 2020 Research and Innovation Framework Programme of the European Commission, Research Directorate-General, Grant Agreement No. 723770
Instituto de Salud Carlos III (ISCIII)
Monforte de Lemos 5, 28029 – Madrid, Spain
era@isciii.esCoordinator
Ignacio Baananteibaanante@isciii.es
+34 9182 22576Instituto de Salud Carlos III (ISCIII)
Monforte de Lemos 5, 28029 – Madrid, Spainma.valencia@isciii.es+ 34 91 822 2227VDI Technologiezentrum GmbH
Dr. Olaf Rotthausrotthaus@vdi.de+49 211 6214 233Ⓒ All rights reserved EuroNanoMed III, 2018
